PRIMARY INTRACRANIAL GERM-CELL TUMOURS IN ADULTS

Evaluation and treatment protocol

Dutch Neuro-Oncology Society
(Landelijke Werkgroep Neuro-Oncologie, LWNO)

Revision 1 - February, 2022

Netherlands Comprehensive Cancer Organisation
(Integraal Kankercentrum Nederland)
Utrecht
1 Working group

Chairman
- J.E.C. Bromberg, MD, PhD, neurologist, Erasmus MC, Rotterdam, j.bromberg@erasmusmc.nl

Working group members
- J.M.M. Gijtenbeek, MD, PhD, neurologist, Radboud UMC, Nijmegen, j.gijtenbeek@neuro.umcn.nl
- E. Kurt, MD, neurosurgeon, Radboud UMC, Nijmegen, Erkan.Kurt@radboudumc.nl
- M.E. van Linde, MD, medical oncologist, Amsterdam UMC, Amsterdam, m.vanlinde@amsterdamumc.nl
- C. van Rij, MD, radiation oncologist, Erasmus MC, Rotterdam, c.vanrij@erasmusmc.nl
- C.C.D. van der Rijt, MD, PhD, medical oncologist, Erasmus MC, Rotterdam, c.vanderrijt@erasmusmc.nl
- A.T. Swaak-Kragten, MD, radiation oncologist Erasmus MC, Rotterdam, a.swaak@erasmusmc.nl
- W. Taal, MD, PhD, neurologist, Erasmus MC, Rotterdam, w.taal@erasmusmc.nl
- F. de Vos, MD, PhD, medical oncologist, UMC Utrecht, Utrecht, f.devos@umcutrecht.nl
- M. Wagemakers, MD, PhD, neurosurgeon, UMC Groningen, m.wagemakers@umcg.nl
- H.L. van der Weide, MD, radiation oncologist UMC Groningen, h.l.van.der.weide@umcg.nl
- P. Wesseling, MD, PhD, neuropathologist, Amsterdam UMC, Amsterdam, p.wesseling@amsterdamumc.nl

Secretary and contact person
- T.T.M. Bluemink-Holkenborg, secretary, Netherlands Comprehensive Cancer Organisation, Utrecht, lwno@iknl.nl

Advisor (cancer registry)
- V.K.Y. Ho, MSc, epidemiologist, Netherlands Cancer Registry, Netherlands Comprehensive Cancer Organisation, Utrecht, v.ho@iknl.nl
# 2 Table of contents

1 Working group ........................................................................................................................................... 2
2 Table of contents ........................................................................................................................................ 3
3 Summary, flowcharts and time schedule ................................................................................................. 4
4 Background ............................................................................................................................................... 5
  4.1 Introduction ........................................................................................................................................ 5
  4.2 Pathology and molecular genetics .................................................................................................... 5
  4.3 Clinical presentation and diagnostic investigations ........................................................................... 7
  4.4 Neurosurgery ..................................................................................................................................... 8
  4.5 Radiotherapy ..................................................................................................................................... 9
  4.6 Chemotherapy ................................................................................................................................. 10
  4.7 Follow-up ......................................................................................................................................... 10
  4.8 Prognosis ......................................................................................................................................... 11
5 Objectives .............................................................................................................................................. 12
6 Eligibility and registration ...................................................................................................................... 13
  6.1 Inclusion criteria ............................................................................................................................... 13
  6.2 Registration ..................................................................................................................................... 13
7 Treatment ................................................................................................................................................ 14
  7.1 Diagnostic work-up ........................................................................................................................... 14
  7.2 Neurosurgery .................................................................................................................................. 14
  7.3 Radiation therapy .............................................................................................................................. 15
  7.4 Chemotherapy, schedules and management .................................................................................. 18
  7.5 Follow-up ......................................................................................................................................... 22
8 Table of evaluations ................................................................................................................................ 23
9 References .............................................................................................................................................. 25

Appendix A: Checklist protocollaire behandeling met PEI bij intracerebrale non-germinomen ................. 29
Appendix B: ZUBROD-ECOG-WHO Performance Status .......................................................................... 32
Appendix C: RTOG neurologic function status ......................................................................................... 33
Appendix D: MR imaging – minimal requirements .................................................................................... 34
3 Summary, flowcharts and time schedule

Flowchart intracranial germ-cell tumors

7.1 Diagnosis / extent of disease <4 week (max 6 weeks)

7.1 Suspected germ-cell tumor in adult

- MR- neuraxis

- 7.2 Hydrocephalus

- 7.2 Clinical and physical work-up:
  - MRI neuraxis
  - CT chest/abdo, tests ultrasound
  - Tumor markers (serum, CSF, WHO PFS)

- 4.3.8 Serum AFP or CSF

- 7.1 Clinical and physical work-up:
  - CT chest/abdo, tests ultrasound
  - Tumor markers (serum, CSF, WHO PFS)

- 4.3.8 Serum AFP or CSF

- 26 ug

Yes

No

Germinoma

7.2 Biopsy (if not done)

Non-germinoma

6.2 Registration

Treatment

Acute visual deterioration from a supratentorial mass

- 7.2 Surgical resection

- 7.3 Radiotherapy whole ventricle and tumour bed 24 Gy, boost to tumour bed 26 Gy Total dose tumour bed 40 Gy

Loculated disease

- Yes (MO)

- 7.3 Radiotherapy craniosexual 24 Gy, boost to tumour bed and metastases 16 Gy Total dose tumour and metastases 30 Gy

No (MO)

Acute visual deterioration from a supratentorial mass

Mature teratoma with normal tumour markers

- Yes

- 7.4 Chemotherapy (v. Gossypol, Etoposide, Ifosfamide (FEP))

No

Located disease

- ER

- 7.2 Extensive surgical resection (if possible and solitary)

DRO

7.2 Radiotherapy (3-4 weeks), Tumor bed 54 Gy

7.3 Radiotherapy (within 3-4 weeks), Craniosexual 50.4 Gy Tumor bed and cranial metastases 25.4 Gy Total dose 59 Gy (total dose spinal metastases 50.4 Gy)
4 Background

4.1 Introduction

Intracranial germ cell tumours (GCTs) are rare tumours of childhood and adolescence with an incidence of 0.1–0.2 / 100 000 per year in children up to the age of 15. In the past 10 years only 3–4 patients aged 18 or over were diagnosed annually with an intracranial GCT in The Netherlands. GCTs are heterogenous with respect to their histology, biological profile and response to treatment and may or may not secrete tumour markers (AFP and/or Beta-HCG) into serum and/or CSF. Two main groups are distinguished: the germinomas and the non-germinomatous germ-cell tumours (NGGCT). Germinoma is the most common subtype accounting for approximately two thirds of the germ-cell tumours and is histologically identical to testicular seminoma and dysgerminoma of the ovary. The NGGCTs are histologically differentiated into embryonal cell carcinoma, yolk sac tumour, choriocarcinoma and mature or immature teratoma. Mixed tumours of various subtypes account for 30% of CNS germ-cell tumours. Prognosis is highly variable and depends on the histology and dissemination. Localised germinomas are exquisitely radiosensitive and can be cured with radiotherapy alone, although metastases can develop occasionally. Mature teratomas can be cured if complete resection can be achieved. The other NGGCTs are associated with the worst prognosis with 5-year survival rates in the range of 9–49% even with aggressive treatment.

Germ-cell tumours most frequently develop at or around puberty or and in the second or third decade of life. Given the rarity of this disease in adults literature for this patient population is scarce and prospective studies have not been performed. Prospective co-operative studies have, however, been performed in children and may to some extent be extrapolated to adults.

Because of the rarity of the disease, prospective studies are difficult to perform. Therefore a protocol has been set up for diagnosis and treatment based on the available literature in order to achieve uniform treatment of adult patients with primary intracranial germ-cell tumours within The Netherlands and allow prospective toxicity and efficacy data to be collected for a larger number of patients than is feasible in a single centre. The current guideline is aimed at patients over the age of 18 and based on an on-going observational protocol by the International Society for Paediatric Oncology (SIOP) with adaptations for expected differences between children and adults. Previously, in patients with intracranial germinoma, trials combining chemotherapeutic schemes with focal radiotherapy have shown poorer relapse free survival than after craniospinal radiotherapy alone. However, more recent data in adolescents and young adults, although also retrospective, appear to challenge this to a certain extent. Although in developing children toxicity of cranial irradiation has incited studies, including the current SIOP protocol, further investigating chemoradiation, in adults the toxicity of radiotherapy is less and does not seem to warrant the risk of inferior tumour control.

Given the limited experience with this disease referral to a neuro-oncological centre is advised. Patients should be included in prospective studies whenever possible.

4.2 Pathology and molecular genetics

The accurate histological (sub)classification of germ-cell tumours of the CNS is critical for treatment planning and prognosis. Two main groups are distinguished: the germinomas and the non-germinomatous germ cell tumours (NGGCT). While germinoma and teratoma are frequently encountered as pure tumor types, other intracranial germ cell neoplasms are often of mixed histologic composition.

World Health Organization classification of intracranial germ cell tumours
Germ-cell tumours of the CNS have been assumed to originate from primordial germ cells that either migrate in aberrant fashion, or home to the embryonic CNS rather than the developing genital ridges. This hypothesis is, however, controversial. An alternative explanation for the occurrence of these intracranial germ cell tumours is derivation of neural stem cells that acquire pluripotent capacity. The exact molecular pathways leading to oncogenesis of germ cell tumours of the CNS are not known. Germ cell tumours may show pure germ cell differentiation (germinoma; synonym for lesion with same histology in testis ‘seminoma’ and in ovary ‘dysgerminoma’) or somatic differentiation. The existence of a common cell of origin may help to explain the histological heterogeneity within mixed malignant germ cell tumours.

Subtypes of non-germinomatous germ cell tumours can be distinguished based on radiological, pathological (incl. immunohistochemical) features and levels of particular markers in blood and/or cerebrospinal fluid (CSF).

Most germ-cell tumours show immunohistochemical staining for placenta-like alkaline phosphatase (PLAP). Germinomas usually express c-Kit (CD117), the receptor for stem cell factor, an important mitogen for normal germ cells. Embryonal carcinomas are frequently CD30 positive. Teratomas typically show components of all three germ layers which may be mature and/or immature in aspect. Examples of mature components are epidermis with skin appendages (incl. hair follicles/hair), teeth, cartilage, bone, glial and thyroid tissue. Immature neural tissue with neurotubular structures is frequently seen in immature teratomas.

### 4.2.1 Molecular biology

Germ-cell tumours of the CNS (beyond early childhood), show complex chromosomal anomalies including gains of chromosomes 12p, 8q, 1p and X, as well as losses of 11q, 13 and 18q. Whether 12p gain, isochromosome 12p formation , and X duplication, especially characteristic of testicular and mediastinal germ-cell tumours, occur at comparably high frequency in CNS tumours is debated (Louis, WHO). Klinefelter syndrome (47, XXY) is associated with an increased risk of intracranial germ-cell tumours. Up till now, the contribution of molecular analysis in the diagnosis and further characterization of germ-cell tumours is limited.

### 4.2.2 Biological characteristics

GCTs may secrete specific tumour markers including alpha-fetoprotein (AFP) and human chorionic gonadotropin (β-HCG). AFP is normally synthesized by yolk sac endoderm; high levels typically signal the presence of yolk sac tumour elements. Marked elevations of β-HCG suggest that components of choriocarcinoma are present, since β-HCG is normally secreted by syncytiotrophoblastic cells. See the section clinical presentation and diagnostic investigations for the implications of these markers for diagnosis and treatment.
4.3 Clinical presentation and diagnostic investigations

4.3.1 Clinical presentation
The symptoms and signs at presentation of GCTs and their appearance are dependent on the site of involvement and on histological tumour types. Typical locations are pineal region (51%) and supra-sellar (30%) with at least 15% having tumours at multiple sites. Especially germinomas tend to bifocal location in pineal and suprasellar regions without metastasizing elsewhere in about 25-30% of cases. The vast majority (95%) of patients with tumours in the pineal region presents with symptoms and signs of intracranial hypertension (headache and papilloedema), including Parinaud’s sign in 73% and diplopia in 24% as a result of obstruction of the aqueduct, invasion of the tectal plate, and hydrocephalus. In patients with suprasellar tumours the majority presents with hypothalamo-hypophysial endocrine disturbances such as diabetes insipidus (86%) or visual disturbances caused by invasion of the optic chiasm (85%). Females older than 12 years frequently manifest primary or secondary amenorrhea (93%).

Tumours in other locations occur much less frequently but tend to cause symptoms and signs compatible with the location. Duration of symptoms before diagnosis is related to velocity of tumour growth, being longer in germinoma (especially of the suprasellar site) in comparison to malignant NGGCTs. Median time from first symptom to diagnosis in suprasellar germinoma is reported to range from 3 to 36 months.

4.3.2 Imaging
MRI is the best imaging modality although CT can contribute information on tumour cellular density and calcification. MRI appearances in typical locations (suprasellar, pineal, bifocal), in conjunction with clinical signs, are strongly predictive of the presence of an intracranial GCT. Germ-cell tumours other than teratomas usually appear as a solid mass, similar of intensity to the grey matter showing prominent enhancement after administration of contrast. Of all tumours in the pineal region, GCTs are the most common, accounting for 31-85% of pineal region tumours. The differential diagnosis in the pineal region includes pineal parenchymal tumours such as the pineocytoma, pineoblastoma and pineal parenchymal tumour of intermediate determination, gliomas, meningioma, ependymoma or metastasis. In the suprasellar sites the main differential diagnosis is Langerhans Cell Histiocytosis and sarcoidosis for small lesions, low-grade glioma or craniopharyngeoma for larger lesions. The most common characteristic of GCTs is calcification of the pineal gland. In addition germinoma may show a calcified pineal gland with symmetric ‘butterfly’ wings of tumour and cases involving both the suprasellar region and pineal gland without dissemination are most likely to be germinomas. Germinomas located in the basal ganglia frequently do not enhance with gadolineum and their mass effect may be faint or absent. Teratomas frequently have heterogeneous signal characteristics due to fat, cysts and calcification, choriocarcinoma may have intense contrast enhancement and a high propensity for intratumoral haemorrhage and pineocytoma show a slightly increased signal intensity on FLAIR and T2/weighted images and are likely to have a cystic component. However, to obtain a definitive diagnosis, biopsy must be performed in all cases unless pathognomonic serum or CSF elevation of tumour markers can be demonstrated.

4.3.3 Tumour Markers
GCTs may secrete specific tumour markers: a-fetoprotein (AFP) and β-HCG, which are not produced by any other primary intracranial tumour. One or both of these markers are elevated at diagnosis in the majority of patients with malignant NGGCTs (80% in the serum, >60% in CSF), and their presence, in conjunction with consistent MRI appearances, is sufficient for the diagnosis without the need for biopsy. AFP concentration > 1000 ng/ml in serum or CSF at diagnosis and residual disease after treatment have been found to be adverse prognostic factors for relapse in NGGCTs.
Yolk sac tumours typically secrete alpha-fetoprotein (AFP) and choriocarcinomas human chorionic gonadotropin (HCG).\(^{11}\) Pure embryonal carcinoma and teratomas are usually not associated with specific tumour markers in blood or CSF.

<table>
<thead>
<tr>
<th>Histology</th>
<th>Clinical behaviour</th>
<th>Tumour markers</th>
<th>Sensitivity to</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>AFP</td>
<td>total HCG</td>
</tr>
<tr>
<td>Germinoma</td>
<td>Malignant</td>
<td>-</td>
<td>(+)</td>
</tr>
<tr>
<td>Embryonal CA</td>
<td>malignant</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Yolk sac tumour</td>
<td>malignant</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Choriocarcinoma</td>
<td>malignant</td>
<td>-</td>
<td>+++</td>
</tr>
<tr>
<td>Teratoma (benign)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

AFP is a glycoprotein with a half-life of 5 days. The cut-off value for germ-cell tumours (serum) is 25 ng/ml (=25 μg/l). Total HCG is produced by the placenta or similar structures. Half-life is 16 hours, normal laboratory value is <5 IU/l.

In germinomas AFP is never elevated. However, germinoma may be associated with mild elevation of total HCG (generally less than 50 IU/l in serum and CSF) indicating the presence of syncytiotrophoblastic cells. In this protocol biopsy will be performed in patients with normal AFP and elevated β-HCG.

### 4.4 Neurosurgery

#### 4.4.1 Background
Because radiotherapy and chemotherapy are the backbone of treatment for patients with germinomas as well as non-germinomatous germ cell tumours, the indication for extensive neurosurgical procedures is limited. In general, the role of neurosurgery in patients with a suspected germ cell tumour consists of a biopsy in order to confirm the diagnosis. Even biopsy is not indicated when the patient with a suspected germ-cell tumour shows characteristic elevation of tumour markers in blood and/or CSF or typical bifocal pineal and suprasellar disease on cranial MRI without further dissemination. The value of extensive surgical resections at diagnosis is unproven\(^ {12}\) and may even lead to neurological and endocrinological deterioration.\(^ {13}\)

#### 4.4.2 Tumour biopsy and tissue sampling
A disadvantage of biopsy is the risk of sample error, which can lead to an inaccurate tissue diagnosis, especially in those patients who do have a mixed germ cell tumour (tumour contains both germinoma and non-germinoma components). Precise data on the risk of sample error are lacking, but the risk is considered to be low.\(^ {14}\) Biopsy can be performed either with neuronavigation guided techniques, stereotactic procedures as well as via an endoscopic approach.\(^ {15}\)

#### 4.4.3 Treatment of hydrocephalus
In cases of hydrocephalus CSF shunting may be necessary. If technically possible, an endoscopic third ventriculostomy is preferred to a ventriculoperitoneal shunt because of a lower risk of dissemination, although even with ventriculostomy it has been described.\(^ {17}\) External ventricular drainage may be a temporary solution. An additional benefit of neuroendoscopy is the ability to simultaneously perform tumour biopsy.\(^ {15}\) Collection of CSF (to assess tumour markers and cytology) is strongly recommended and easy to perform in a neuroendoscopic procedure or ventriculoperitoneal shunt placement. CSF must be collected before biopsy or surgery of the tumour. If the pre-operative sample is from the ventricles only, resampling of lumbar CSF 2-3 weeks postoperatively is advised in case of tumor cells in the CSF.
ventricular CSF since this may denote local tumor rather than true leptomeningeal spread. If CSF cannot be obtained for any reason the patient should be treated as M+.

4.4.4 Indications for extensive procedures

1) Patients who suffer acute obstructive visual deterioration from a suprasellar mass

2) Proven mature teratomas (after a previous biopsy) with normal tumour markers. In these patients gross total resection is recommended since surgery is curative and no further interventions are required.

3) Patients with a single residual mass after chemotherapy
   a) within the non germinoma group: The tumour recurrence rate is much higher and the outcome shows a poorer prognosis when compared with patients who do not have a residue. Non-germinomatous GCT often are relatively resistant to conventional chemotherapy and radiotherapy; total resection by second look operation improves disease control. This is in line with treatment of extracranial germ-cell tumours.
   b) within the germinoma group: if responsive to radiotherapy these should not be resected but a watch-and-wait strategy should be the policy. 50

4) Patients with localized disease, both germinoma and non-germinoma, who do not show any response to chemoradiotherapy.

The optimum timing of surgery is after the end of chemotherapy, but it may also be considered following radiotherapy.

4.5 Radiotherapy

4.5.1 Germinoma

In the literature mainly retrospective research for germinoma in adults is reported and most publications report on a combination of children and young adults. In general, radiotherapy alone can cure in excess of 90% of patients with germinomas with either craniospinal irradiation (CSI)18-23 or whole-ventricular irradiation (WVI).19;24-26 The formerly used irradiation of the entire craniospinal axis has been abandoned in non-metastatic disease for reasons of significant endocrine and neurocognitive toxicities and based on several reports of equivalent control rates with the use of limited irradiation to the intracranial ventricular system21;22;24;27-31 for metastasized germinoma CSI is still indicated.

For germinoma, it is important that radiation fields cover the whole peri-ventricular area and not only the local tumour bed in order to achieve same local control as with CSI. Only one publication reports solely on adult patients with a median age of 24 years. After a median follow-up of about 11 months and low-dose craniospinal radiotherapy of 25 Gy with a boost dose to the tumour to a total dose of 40 Gy they have observed no relapses and no deaths.32 Earlier reports concluded that germinoma occurring in the basal ganglia would require whole brain irradiation, as they invade deep brain tissue and relapses can occur outside of the peri-ventricular area.33;34 However, newer published evidence (in children) supports the use of whole ventricular irradiation (WVI) for these patients as well as for those with bifocal tumours in case chemotherapy was added.35;36 For bifocal tumours WVI is sufficient if there is no other evidence of metastatic disease or positive CSF.37

4.5.2 Non-germinoma

For non-germinoma, radiation therapy alone is rarely curative but an essential treatment modality. Most tumours relapse within 18 months.38 Chemotherapy alone is also not sufficient as high relapse rates of 50% have been reported.39;40 The combination of radiotherapy with platinum based chemotherapy plays a key role in non-germinomatous malignant germ cell tumours. Published evidence reports on the important role of radiotherapy in these malignant intracranial tumours. A dose higher than 50 Gy should be given to the local tumour bed (SIOP CNS GCT 96). For non-metastasised tumours focal irradiation is sufficient when combined with platinum-based chemotherapy.
4.6 Chemotherapy

4.6.1 Germinoma
Large retrospective series and prospective trials have shown that irradiation alone is a safe therapy yielding high cure rates. In view of the excellent results of radiotherapy only, chemotherapy is not indicated for adults with intracranial germinoma, regardless of the disease stage. The estimated relapse free survival rate was 91% with a median follow-up time of 59.5 months (range 3–180 months). Trials combining chemotherapeutic schemes with focal radiotherapy did not improve the relapse free survival. In contrast to the pediatric population, adult tolerance of radiotherapy is acceptable whereas chemotherapy toxicity is greater. The incentive to decrease radiotherapy dose and replace it with chemotherapy is therefore largely absent. However, a recent retrospective series in adolescents and young adults appears to challenge this finding. Results of the prospective SIOP study are awaited and will hopefully give a better basis for therapeutic advice; until then the protocol does not in general advise chemotherapy in germinoma.

4.6.2 Non-germinomatous germ-cell tumours
Non-germinomatous germ-cell tumours display a high responsiveness to chemotherapeutic agents, although chemotherapy alone is insufficient to achieve cure, as it is associated with a 50% relapse rate in 26 patients in the Memorial Sloan Kettering Cancer Centre Group cohort. In the SIOP CNS GCT 96 trial, 149 patients with intracranial non-germinoma were treated with four cycles of cisplatin, etoposide and ifosfamide (PEI). In non-metastatic disease, focal irradiation with 54 Gy was then administered, while patients with metastatic disease were treated with craniospinal irradiation with 30 Gy and a boost of 24 Gy to all sites of visible tumour on MRI. The study resulted in 10 years event free survival of 70% and in 10 years overall survival of 67% with a median follow-up of 40 months. The combination of radiotherapy with platinum-based chemotherapy has a key role in achieving optimal outcome and has now become the treatment standard in this group of tumours. It has not been proven that high-dose chemotherapy plus autologous haematopoietic stem cell support given as first-line therapy increases survival. However, in a review article, a 10% improvement in survival with early intensification of salvage treatment using high-dose chemotherapy was mentioned. Therefore, high-dose chemotherapy should not be used outside of a prospective clinical trial.

Salvage therapies for relapsed GCTs include surgery, local or whole neuroaxis irradiation, and myeloablative chemotherapy with autologous blood stem cell rescue. There is no preferred treatment scheme, although good efficacy has been reported with myeloablative chemotherapy with stem cell rescue.

4.7 Follow-up
Most cases of relapsed CNS germ-cell tumours occur within 5 years and at the primary tumour site although in up to 30% of cases distant metastases occur. Median time to relapse was 12 months (range 7-120), though in germinoma median time to first recurrence has been reported to be 50 months after initial treatment. Therefore surveillance should be most intensive in the first year after treatment and should continue at least 5 years, preferably 10 years.
### 4.8 Prognosis

Prognosis is determined by pathology of the tumour, extent of disease and presence or absence of elevated tumour markers. Overall survival in patients with pure germinoma at 5 years is >90% after radiotherapy only, 5-year survival in mixed germinomatous and non-germinomatous GCT is around 70%, in NGGCT it is less than 50%. Since elevated AFP is a marker of the NGGCTs this coincides with a poorer prognosis. In patients with pure germinoma, elevated serum β-HCG does not seem to influence prognosis although a small study in 12 patients found a poorer prognosis in patients with elevated β-HCG in CSF. In patients with NGGCTs survival was worse in patients with elevated β-HCG after chemotherapy-based treatment with a HR of death of 1.9 for patients with raised markers.
5 Objectives

The objectives of the current protocol are to:
1) treat all adult patients with a primary intracranial germ-cell tumour in The Netherlands in a uniform manner through a comprehensive protocol;
2) document the feasibility of this treatment protocol by recording side-effects and actually administered treatment in a standardized fashion;
3) document the outcome of adult primary intracranial germ-cell tumours in EFS and OS after treatment in this standardized treatment protocol;

To this end, all patients will be prospectively registered in a central database.
6 Eligibility and registration

6.1 Inclusion criteria

Diagnosis of primary intracranial germ-cell tumour
- Except in specific situations as described in section 7.1, diagnosis should be pathologically verified and be confirmed by central review whenever possible. Central review will be done by:

  Prof. dr. J.M. Kros, neuropathologist,  
  Erasmus Medical Centre/location Centrum  
  Dr. Molewaterplein 40  
  3015 GD ROTTERDAM,  
  email: j.m.kros@erasmusmc.nl

- Age ≥ 18

6.2 Registration

After diagnosis and informed consent all adult patients with a primary CNS germ-cell tumour should be registered at the Erasmus MC department of Neuro-Oncology by email: neuro-onco-trials@erasmusmc.nl

At least the following information should be registered for each patient:
- date of birth;
- sex;
- patient hospital registration number;
- treating physician; and
- date of registration

The original signed patient information sheet should be kept in the local patient file.
7 Treatment

7.1 Diagnostic work-up

Complete assessment of the extent of disease using MR imaging of brain and spine, evaluation of tumour markers in serum and CSF and investigation of CSF for leptomeningeal dissemination is essential to determine optimal treatment. In addition a CT of thorax and abdomen and in men a testicular ultrasonography should be performed to exclude a non-CNS primary. Diagnostic investigations are summarized in the flow-chart (page 4) and the tables (page 23, 24). In addition endocrinologic screening is advised.

Imaging
Cranial MRI should be performed in all cases pre-operatively and within 48 hours following surgery if resection is performed (not required after biopsy only). Spinal MRI should ideally be performed before lumbar puncture and surgery and should include the full spine (C0–S3). Pre-contrast T1 sequences are mandatory, especially after surgery.

Tumour Markers
In patients suspected of harbouring an intracranial germ-cell tumour, assessment of tumour markers (AFP and HCG) in both serum and CSF must be performed. Since elevated markers in the context of a primary intracranial tumour are diagnostic of a germ-cell tumour, assessment of markers may obviate the need for biopsy as outlined in the flow-chart. Furthermore, elevated HCG may distinguish between germinoma and NGGCT.

Tumour markers are also used for response evaluation. Therefore, in patients with raised markers at diagnosis, tumour markers are to be repeated in serum if > 2 weeks have elapsed between diagnosis and the planned start of treatment and in CSF if > 4 weeks have elapsed.

CSF examination
GCTs may disseminate through the CSF and it is of utmost importance to stage patients completely before starting treatment. If possible, CSF should be sampled before neurosurgical intervention for pathologic examination and evaluation of tumour markers. If, however, lumbar puncture is not possible before surgery, CSF may be sampled peri-operatively but before biopsy. If the pre-operative sample is from the ventricles only, resampling of lumbar CSF 2-3 weeks postoperatively is advised in case of tumor cells in the ventricular CSF since this may denote local tumor rather than true leptomeningeal spread.

If CSF cannot be obtained for any reason the patient should be treated as M+.

Biopsy
Biopsy is mandatory in all patients except those with: typical MRI findings and elevated serum and/or CSF AFP (> 25 μg/l) (diagnosis NGGCT)

Central pathology review is advised in all patients.

Systemic evaluation
Presentation of a systemic germ-cell tumour with an intracranial metastasis is exceedingly rare. Nevertheless, given the clinical consequences of concurrent systemic disease, CT evaluation of chest and abdomen and, in males, testis ultrasonography is advised.

7.2 Neurosurgery

Tumour biopsy
Biopsy can be performed either with neuronavigation guided techniques, stereotactic procedures as well via an endoscopic approach.
Treatment of hydrocephalus
In cases of hydrocephalus CSF shunting may be necessary. If technically possible, an endoscopic third ventriculostomy is preferable to placement of a ventriculoperitoneal shunt. An additional benefit of neuroendoscopy is the ability to simultaneously perform tumour biopsy. Collection of CSF (to assess tumour markers and leptomeningeal dissemination) is strongly recommended and easy to perform in a neuroendoscopic procedure or ventriculoperitoneal shunt placement. CSF must be collected before biopsy or surgery of the tumour. If the pre-operative sample is from the ventricles only, resampling of lumbar CSF 2-3 weeks postoperatively is advised in case of tumor cells in the ventricular CSF since this may denote local tumor rather than true leptomeningeal spread. If CSF cannot be obtained for any reason the patient should be treated as M+.

Indications for extensive procedures may be
1) Patients who suffer acute obstructive visual deterioriation from a suprasellar mass.
2) Proven mature teratomas (after a previous biopsy) with normal tumour markers. In these patients gross total resection is recommended since surgery is curative and no further interventions are required.
3) Patients with a single residual mass after chemoradiotherapy
   a) within the non germinoma group: the tumour recurrence rate is much higher and the outcome shows a poorer prognosis, when compared with patients who do not have a residue.
   b) within the germinoma group residual lesions that have responded to radiotherapy should not be resected but a watch and wait strategy should be the policy.
4) Patients with localized disease, germinoma or non-germinoma, who do not show any response to chemoradiotherapy.

7.3 Radiation therapy

<table>
<thead>
<tr>
<th>CSI</th>
<th>WVI</th>
<th>Tumour Bed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protons</td>
<td>Protons or Photons</td>
<td>(Stereotactic) Photons</td>
</tr>
</tbody>
</table>

7.3.1 Treatment planning
Immobilisation and treatment position
- Patients will be immobilised according to institutional practice.
- Patients receiving CSI RT can be treated either prone or supine.
- For the tumour bed and/or the ventricular irradiation, patients should preferably be treated in a supine position (accuracy reasons).

Imaging for treatment planning
Tumour definition
- Planning CT and 3D MRI with contrast (T1 weighted) and T2/FLAIR for delineation of focal and whole ventricular target volumes.
- Preoperative and pre-chemotherapy MRI scans need to be used and fused to the planning scan.

Target volumes (based on SIOP CNS GCT II protocol 2009)
Tumour bed (as boost or sole treatment)
- Gross Tumour Volume (GTV) includes the initial tumour extension adapted to anatomical changes and any post-chemotherapy (or post-surgery) residue.
- Clinical target volume (CTV): GTV plus a 3D-margin; when originating either in the suprasellar or pineal region a 3D-margin of 5 mm will be added. In “atypical” primary sites where local infiltration of normal tissues could be suspected (e.g. basal ganglia or thalamus) a margin of 10 mm is recommended.
• Depending on the size of the target volume, the preferred technique for tumour bed irradiation only is either stereotactic radiotherapy (< 3-4 cm) or proton therapy (> 4cm).

**Whole ventricles (WVI)**
- GTV: the lateral ventricles, 3rd ventricle and 4th ventricle as visualised on 3D FLAIR MRI including the tumour bed (as defined above).
- CTV: GTV plus a 3D-margin of 5 mm.
- The preferred technique for WVI is either IMRT/VMAT or proton therapy.

**Craniospinal axis (CSI)**
- CTV: the entire subarachnoidal space is included. Specific attention should be given to inclusion of the cribiform plate, temporal fossa, optic nerves, Meckel’s cave and other cranial nerve foramina, the lateral extensions of the spinal nerves and the inclusion of the entire thecal sack caudally as visible on MRI.
- The preferred technique is intensity modulated proton therapy. Due to the limited availability of proton therapy, a quick start of the referral procedure is mandatory. In case proton therapy is not available or achievable the patient will be treated with photon therapy, either 3D CRT or IMRT/VMAT.
- Using highly conformal advanced radiation techniques makes image guidance during delivery very important.

**Metastasis boost**
- GTV: initial extension of metastatic tumour volumes.
- CTV: GTV + 3D margin 10 mm, adapted to the anatomy (no extension outside the craniospinal axis volume).

**Organs at risk (OAR)**
ALARA (As Low As Reasonably Achievable) principle, without compromising CTV.

### Cranial irradiation

<table>
<thead>
<tr>
<th>OAR</th>
<th>Max Dose (Gy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brainstem surface</td>
<td>60</td>
</tr>
<tr>
<td>Brainstem interior</td>
<td>54</td>
</tr>
<tr>
<td>Chiasm</td>
<td>55</td>
</tr>
<tr>
<td>Optic Nerves</td>
<td>55</td>
</tr>
<tr>
<td>Retina</td>
<td>45</td>
</tr>
<tr>
<td>Cochlea</td>
<td>45</td>
</tr>
<tr>
<td>Pituitary Gland</td>
<td>45</td>
</tr>
<tr>
<td>Spinal Cord</td>
<td>54</td>
</tr>
</tbody>
</table>

(ref Lambrecht 2018)  

### CSI

<table>
<thead>
<tr>
<th>OAR</th>
<th>Max Dose (Gy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spinal cord</td>
<td>54</td>
</tr>
<tr>
<td>Thyroid</td>
<td>30</td>
</tr>
<tr>
<td>Testes</td>
<td>2</td>
</tr>
<tr>
<td>Ovaries</td>
<td>6</td>
</tr>
<tr>
<td>Kidney (bilateral)</td>
<td>Mean dose &lt;15-18 Gy V12 &lt; 55 %</td>
</tr>
</tbody>
</table>

(ref Rubin 1989, Quantec)
7.3.2 Pure germinoma

**Indication**

AFP not increased in serum or CSF. β-HCG value plays no role for decision making of radiotherapy.

**Timing**

RT should start as soon as possible but no later than 4-6 weeks from diagnosis. The largest prescribed volume should be treated first.

**No metastases (M0)**

**Dose and fractionation**

<table>
<thead>
<tr>
<th>Volume</th>
<th>Total dose</th>
<th>Fraction dose</th>
<th>No. Fractions</th>
</tr>
</thead>
<tbody>
<tr>
<td>WVI and tumour bed (ventricles and tumour + 5mm)</td>
<td>24</td>
<td>1.6</td>
<td>15</td>
</tr>
<tr>
<td>Boost to tumour bed (Tumour + 5 mm)</td>
<td>16</td>
<td>1.6</td>
<td>10</td>
</tr>
<tr>
<td>Tumour bed total</td>
<td>40</td>
<td>1.6</td>
<td>25</td>
</tr>
</tbody>
</table>

*To note: 1) Germinoma occurring in the basal ganglia require a larger additional CTV margin in addition to the ventricles (10 mm); 2) Bifocal tumours (i.e. tumours both in the pineal and suprasellar region) should also be treated by WVI; 3) Incompletely staged germinoma should also receive CSI; 4) if component of teratoma, incompletely or not resected: increase tumourbed dose boost up to 54.4 Gy.*

**Metastases (M1) or incompletely staged**

**Indication:** diagnosis based on imaging and/or positive CSF or incomplete staging

**Dose and fractionation**

<table>
<thead>
<tr>
<th>Volume</th>
<th>Total dose</th>
<th>Fraction dose</th>
<th>No. Fractions</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSI</td>
<td>24</td>
<td>1.6</td>
<td>15</td>
</tr>
<tr>
<td>Boost to tumour bed and metastases (Tumour + 5 mm)</td>
<td>16</td>
<td>1.6</td>
<td>10</td>
</tr>
<tr>
<td>Tumour bed total</td>
<td>40</td>
<td>1.6</td>
<td>25</td>
</tr>
</tbody>
</table>

*To note: If component of teratoma, incompletely or not resected increase tumourbed dose boost up to 54.4Gy*

7.3.3 Non-germinomatous germ-cell tumours

**Indication**

- teratoma, embryonal carcinoma, choriocarcinoma, yolk sac tumours and mixed germ cell tumours

**Timing**

- **After chemotherapy:** RT will start after haematological recovery of the patients, usually within 3-4 weeks following the last cycle of chemotherapy.
- **Without chemotherapy:** RT should start as soon as possible but no later than 4-6 weeks from diagnosis.
- The largest prescribed volume should be treated first.
No metastases (M0) and treatment with platinum based chemotherapy
Dose and fractionation

<table>
<thead>
<tr>
<th>Volume</th>
<th>Total dose</th>
<th>Fraction dose</th>
<th>No. Fractions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumour bed (pre-chemo/surgery tumour + 5mm)</td>
<td>54</td>
<td>1.8</td>
<td>30</td>
</tr>
</tbody>
</table>

Metastases (M1)

Indication: diagnosis based on imaging and/or positive CSF

Dose and fractionation

<table>
<thead>
<tr>
<th>Volume</th>
<th>Total dose</th>
<th>Fraction dose</th>
<th>No. Fractions</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSI</td>
<td>30.6</td>
<td>1.8</td>
<td>17</td>
</tr>
<tr>
<td>Boost to tumour bed and intracranial metastases (Pre-chemo/pre-surgery tumour + 5 mm)</td>
<td>23.4</td>
<td>1.8</td>
<td>13</td>
</tr>
<tr>
<td>Spinal metastases</td>
<td>19.8</td>
<td>1.8</td>
<td>11</td>
</tr>
<tr>
<td>Total dose to tumour and intracranial metastases</td>
<td>54</td>
<td>1.8</td>
<td>30</td>
</tr>
<tr>
<td>Total dose to spinal metastases</td>
<td>50.4</td>
<td>1.8</td>
<td>28</td>
</tr>
</tbody>
</table>

If more than 2/3 of the spine is involved with macroscopic disease the total dose will be limited to 39.6 Gy (additional boost dose: 9 Gy in 5 daily fractions of 1.8 Gy).

7.3.4 Toxicity of CSI
Acute toxicity (up to 3 months after treatment)
The most important acute toxicities of the craniospinal irradiation are bone marrow suppression, headache, nausea, dermatitis, alopecia and fatigue. During radiation, patients should be monitored carefully including weekly blood counts. Toxicity resulting from the higher dose region(s) include temporary focal deficits, which may necessitate treatment with steroids. In case of photon therapy mucositis of the GI tract can be expected.

Late toxicity (months to years after treatment, irreversible)
Whole brain irradiation can cause long term neurocognitive toxicity. The neurocognitive effects can vary in severity, ranging from mild concentration problems or short term memory loss to apathy and intellectual decline, and are not reported in great detail for the adult population. Pituitary dysfunction can occur after dosis as low as 20 Gy, and survivors should be screened for endocrine disorders once a year. Other long term side effects include hearing loss and fibrosis of back musculature. In case of photon therapy reduced fertility, cardiovascular morbidity can be seen.

7.4 Chemotherapy, schedules and management

7.4.1 Germinoma
In view of the excellent results of radiotherapy only, chemotherapy is not indicated for adults with intracranial germinoma, irrespective of stage.

7.4.2 Non-germinomatous germ cell tumours (PEI also known as VIP)
In view of the poor prognosis of these patients, all patients will be treated with 4 courses of cisplatin, etoposide and ifosfamide (PEI). In males, the possibility of sperm cryopreservation...
should be discussed prior to the initiation of chemotherapy. In females, gonadal protection may be considered, and should be based on local or national recommended practice. After 4 courses, evaluation will take place. All patients will be irradiated after chemotherapy.

Figure 1. Schematic representation of chemotherapy in the treatment

<table>
<thead>
<tr>
<th>4xPEI</th>
<th>Evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>PR/SD</td>
</tr>
<tr>
<td>resection when resectable</td>
<td>palliative radiotherapy</td>
</tr>
<tr>
<td>radiotherapy</td>
<td>radiotherapy</td>
</tr>
</tbody>
</table>

PEI chemotherapy
Each course of PEI consists of:
- Cisplatin 20 mg/m²/day days 1, 2, 3, 4, 5
- Etoposide 75 mg/m²/day days 1, 2, 3, 4, 5
- Ifosfamide 1200 mg/m²/day days 1, 2, 3, 4, 5
Courses should be given at 21 day intervals, subject to count recovery.

Details of chemotherapy administration
It is advised to insert a central venous catheter according to local practice for the delivery of this chemotherapy.
- *Cisplatin* (20 mg/m², days 1, 2, 3, 4, 5) should be given over one hour, and must be accompanied by an adequate diuresis. In the absence of diabetes insipidus (DI), this should be achieved with a forced diuresis according to local practice (with mannitol or furosemide).
- *Etoposide* (75 mg/m², days 1, 2, 3, 4, 5) should be diluted to <0.3mg/ml in 0.9% saline (NaCl) and given over one to four hours (according to institutional practice), prior to cisplatin and ifosfamide.
- *Ifosfamide* (1200 mg/m², days 1, 2, 3, 4, 5) is given after cisplatin, over 3 hours by continuous infusion with hydration and mesna (uromexitan), to prevent bladder toxicity.
Other nephrotoxic drugs, including aminoglycoside antibiotics, should be used with caution with ifosfamide and cisplatin.

Supportive care during chemotherapy
*Mesna*
Mesna should be given, according to local protocol, but at a dose of at least 100-120% of the daily ifosfamide dose, starting prior to cisplatin infusion. It is recommended that this is given as a continuous infusion (alongside or added to hydration fluid). In the rare event of haemorrhagic cystitis, mesna or hydration should be increased and diuretics added, according to institutional practice.

*Hydration fluid*
Hydration fluid should commence at least one hour before start chemotherapy and continue throughout the infusions of cisplatin and ifosfamide, at a total rate (including chemotherapy) of at least 125ml/m²/hour (3l/m²/day) and continue until 24 hours from the end of the cisplatin infusion. 2.5% glucose 0.45% saline should be used with potassium, magnesium and calcium additives. The following concentrations are recommended:
• 20 mmol KCl per litre
• 10 mmol MgSO4 per litre
• 0.6 mmol Ca Gluconate per litre

Depending on the volumes used for drugs, the total fluid volume in addition to the hydration fluid is likely to be significant. Consideration should be given to capping this at 3.5l/m²/day or 4l/m²/day.

Note: For patients with diabetes insipidus, consultation with an endocrinologist is advised in order to prevent severe electrolyte disturbances. Particular attention must be paid to urine output and plasma electrolytes in these patients, especially in those without perception of thirst.

Anti-emetic treatment
Recommended anti-emetic treatment includes a 5HT3-antagonist, metoclopramide and aprepitant. Administration of steroids (e.g. dexamethasone) during chemotherapy should be avoided if at all possible, and only used for anti-emesis if other therapies fail.

Prophylactic antibiotics
The prophylactic use of cotrimoxazole (sulfamethoxazole/trimethoprim) is optional and should be based on local practice, as no case of pneumocystis jirovecii pneumonitis has been reported in the SIOP CNS GCT 96 series. Prophylactic antibiotic/antifungal decontamination may be used if it is the normal practice in the treating hospital. The choice of antibiotics used during episodes of febrile neutropenia should be based on local guidelines.

Hematopoietic growth factors
Hematopoietic growth factors are not indicated after the first course. In case of neutropenic fever or delay of next course of chemotherapy due to neutropenia, administration of G-CSF is indicated (rather than decreasing dose).

7.4.3 Toxicity, dose modification and treatment delay
Hematological toxicity
• Courses of chemotherapy should be delayed until haematological recovery from the previous course has taken place, defined by neutrophils of at least 0.5 x 10⁹/l and platelets 100 x 10⁹/l.
• In case of febrile neutropenia: consider adding granulocyte-colony stimulating factor in following courses.
• In case of macroscopic hematuria (>10 RBC/HPF): elevate mesna dose to 2400 mg/m²/day; ensure adequate hyperhydration with normal serum electrolytes and sufficient urine output. Consider intravesical treatment with NaCl 0.9%. In acute severe cases: consult an urologist immediately for bladder instillation therapy.

At start of course:
  - neutrophil granulocytes ≥0.5 x 10⁹/l and
  - trombocytes ≥100 x 10⁹/l

Otherwise course should be delayed for one week. If after one week blood counts have recovered, employ 100% dose in case of neutropenia without thrombopenia and add granulocyte-colony stimulating factor. If thrombopenia was the cause for delay, or if granulocyte-colony stimulating factor was already administered after the previous course, a 25% dose reduction of etoposide should be performed. When hematological toxicity requires delay of > 2 weeks despite dose reduction of etoposide, the coordinating team of the LWNO should be consulted.
Ototoxicity (lowest grade of best performing ear)

<table>
<thead>
<tr>
<th>Grade</th>
<th>Subjective hearing loss</th>
<th>Audiometry</th>
<th>Treatment adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>no change</td>
<td>loss &lt; 40 db</td>
<td>None</td>
</tr>
<tr>
<td>1</td>
<td>no change</td>
<td>loss &gt; 40 db at 8000 Hz</td>
<td>None</td>
</tr>
<tr>
<td>2</td>
<td>tinnitus</td>
<td>loss &gt; 40 db at 4000 Hz</td>
<td>switch cisplatin to carboplatin AUC 4</td>
</tr>
<tr>
<td>3</td>
<td>function interference; hearing aid needed</td>
<td>loss &gt; 40 db at 2000 Hz</td>
<td>omit any platinum</td>
</tr>
<tr>
<td>4</td>
<td>deafness not correctable</td>
<td>loss &gt; 40 db at 1000 Hz</td>
<td>omit any platinum</td>
</tr>
</tbody>
</table>

AUC = area under the curve

Nephrotoxicity (cisplatin)
- Calculated GFR <60 ml /min/1.73 m²
- Serum creat >1.5 x ULN

Delay course with one week. After one week delay GFR should be measured by 24 hours urine collection. If repeat GFR still < 60 ml /min/1.73 m², switch cisplatin to carboplatin AUC 6.

Neurotoxicity (Ifosfamide)
Cerebral adverse events can occur and are characterised by diminished consciousness, deliriousness, anxiety and hallucinations. Recovery can be a matter of days to weeks. Beneficial effects were seen by administration of methylene blue 6 x 50 mg/day i.v. and of thiamine 6 x 100 mg in 100 ml NaCl 0.9% in 10 minutes i.v. In subsequent courses, prophylactic methyleneblue 6 x 50 mg IV daily should be considered. In case of recurrence, substitution with cyclofosfamide 800 mg/m² on day 1 only may be considered.

7.4.4 Investigations before each course of chemotherapy
- Clinical examination including neurological assessment and WHO-ECOG performance status
- Weight
- Full blood count
- Blood biochemistry: electrolytes, urea, creatinine, ALT/AST, Alkaline phosphatase, bilirubin, albumin, magnesium, calcium, phosphate
- Serum markers (AFP and total HCG)
- Creatinine clearance calculated by Cockroft-Gault formula
- Pure tone audiometry (if indicated)

7.4.5 Tumour evaluation during chemotherapy

Serum markers
Before each course of chemotherapy, serum markers AFP and HCG will be determined. The calculated half life of AFP is 5–7 days, and for HCG around 50 hours. If markers rise during chemotherapy and if the elevation cannot be accounted for by this half-life, radiotherapy must be considered if imaging studies confirm progression. It is recognized that markers may increase in the first one to two weeks after the first course of PEI (‘surge’) despite chemosensitivity, and calculations should take that into account.
Imaging
After the 4th course of PEI, MRI scanning of the brain will be performed. In case of irresectable progressive disease, 2nd line chemotherapy may be considered after consultation of a specialized centre. Otherwise immediate radiotherapy is advised. In case of suspicion of early progression based on rising markers or neurological symptoms, imaging may be done earlier.

7.5 Follow-up

See Chapter 8, Tables of evaluations.

MR imaging, as well as clinical and neurologic examination and serum tumour markers should be done 6-12 weeks after the end of treatment. Thereafter if possible every 4 months in the first year, every 6 months in the second and third year and yearly thereafter until year 5. The MRI should be made of the brain in all patients. Additionally, in patients with abnormal spinal MRI at diagnosis spinal MRI should be repeated at the end of treatment and thereafter on clinical indication and at least with every other cranial MRI. In NGGCT with elevated markers at diagnosis markers should be evaluated two-monthly after treatment in the first year, 3-monthly in the second year, 6-monthly in the third year and yearly thereafter until 5 years.
### 8 Table of evaluations

#### Table 1. Required evaluations in germinoma patients treated with radiotherapy only

<table>
<thead>
<tr>
<th>Observation</th>
<th>Preoperatively</th>
<th>After resection</th>
<th>Prior to RT</th>
<th>During RT</th>
<th>At the end of RT</th>
<th>After treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical and neurological exam</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>Weekly</td>
<td>X</td>
<td>X&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Weight</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>WHO performance</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td>Weekly</td>
<td>X</td>
</tr>
<tr>
<td>MRI brain</td>
<td>X</td>
<td>X&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td>X</td>
<td>X&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>MRI spine</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X&lt;sup&gt;c&lt;/sup&gt;</td>
<td>X&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>CSF cytology</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSF tumor markers</td>
<td>X&lt;sup&gt;d&lt;/sup&gt;</td>
<td>X&lt;sup&gt;d&lt;/sup&gt;</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Serum tumor markers</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>CBC</td>
<td>X</td>
<td></td>
<td>Weekly</td>
<td></td>
<td>if CSI</td>
<td>X</td>
</tr>
</tbody>
</table>

---

a) Only after resection, not necessary after biopsy: within 48h
b) Every 4 months 1st year, every 6 months second year, yearly thereafter until 5 years
c) Only repeat if positive at outset, at least with alternate brain MRIs and if symptomatic
d) If the pre-operative sample is from the ventricles only, resampling of lumbar CSF 2-3 weeks postoperatively is advised in case of tumor cells in the ventricular CSF since this may denote local tumor rather than true leptomeningeal spread.\(^{51}\)\(^{52}\) If CSF cannot be obtained for any reason the patient should be treated as M+.
Table 2. Required observations in non-germinoma patients treated with chemotherapy and radiotherapy

<table>
<thead>
<tr>
<th>Observation</th>
<th>Preoperatively</th>
<th>Postoperatively</th>
<th>Prior to each PEI</th>
<th>Prior to RT</th>
<th>During RT</th>
<th>At the end of RT (6-12 wks after)</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical and neurological exam</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>Weekly</td>
<td>X</td>
<td>X^c</td>
</tr>
<tr>
<td>Height (prior to first PEI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Performance status</td>
<td>X</td>
<td>X</td>
<td>Weekly</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCI-CTC toxicity</td>
<td>X</td>
<td>X</td>
<td>Weekly</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRI brain</td>
<td>X</td>
<td>X^a</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X^b</td>
<td></td>
</tr>
<tr>
<td>MRI spine</td>
<td>X</td>
<td>X^c</td>
<td></td>
<td>X^c</td>
<td>X^c</td>
<td>X^c</td>
<td></td>
</tr>
<tr>
<td>CSF cytology</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSF tumor markers</td>
<td>X^h</td>
<td>X^h</td>
<td>X^d</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum tumor markers</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X^e</td>
<td></td>
</tr>
<tr>
<td>CBC</td>
<td></td>
<td>X</td>
<td>X</td>
<td>Weekly</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood chemistry ^f</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Audiometry</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X^g</td>
</tr>
</tbody>
</table>

a) Only after resection, not necessary after biopsy: within 48h
b) Every 4 months 1st year, every 6 months second year, yearly thereafter until 5 years
c) Only repeat if positive at outset, at least with alternate brain MRIs and if symptomatic
d) Consider if positive at outset and clinically indicated
e) 2-monthly in 1st year, 3-monthly second year, 6-monthly 3rd year, thereafter yearly until 5 years
f) Sodium, potassium, calcium, magnesium, creatinine, Cockcroft creatinine clearance, blood urea nitrogen, bilirubine, ASAT, ALAT, GGT, LDH. Additionally endocrinologic evaluation if clinically required.
g) Prior to first chemotherapy, thereafter on indication only.
h) If the pre-operative sample is from the ventricles only, resampling of lumbar CSF 2-3 weeks postoperatively is advised in case of tumor cells in the ventricular CSF since this may denote local tumor rather than true leptomeningeal spread. 51 52 If CSF cannot be obtained for any reason the patient should be treated as M+. 
9 References


Appendix A: Checklist protocollaire behandeling met PEI bij intracerebrale non-germinomen

I Behandelschema

<table>
<thead>
<tr>
<th>Medicatie</th>
<th>Dosering</th>
<th>Interval</th>
<th>Toedieningsweg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etoposide (E)</td>
<td>75 mg/m²</td>
<td>dag 1–5</td>
<td>i.v.</td>
</tr>
<tr>
<td>Ifosfamide (I)</td>
<td>1200 mg/m²</td>
<td>dag 1–5</td>
<td>i.v.</td>
</tr>
<tr>
<td>Cisplatine (P)</td>
<td>20 mg/m²</td>
<td>dag 1–5</td>
<td>i.v.</td>
</tr>
<tr>
<td>Mesna</td>
<td>volgens lokaal protocol, 1200-1500 mg/m²</td>
<td>dag 1–5</td>
<td>i.v.</td>
</tr>
</tbody>
</table>

In totaal 4 kuren à 3 weken, klinisch, 5 dagen kuur, 6e dag naar huis

II Voorbereiding en toediening

Bij aanvang van de kuur mag er geen sprake zijn van dehydratie: indien hierop vermoeden bestaat patiënt eerst rehydreren.

<table>
<thead>
<tr>
<th>Medicatie</th>
<th>Dosering</th>
<th>Interval</th>
<th>Toedieningsweg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etoposide (E)</td>
<td>75 mg/m²</td>
<td>in 1000 ml NaCl 0,9%</td>
<td>in 1–4 uur</td>
</tr>
<tr>
<td>Cisplatine (P)</td>
<td>20 mg/m²</td>
<td>in 1000 ml NaCl 0,9%</td>
<td>in 1–3 uur</td>
</tr>
<tr>
<td>Ifosfamide (I)</td>
<td>1200 mg/m²</td>
<td>in 1000 ml NaCl 0,9 %</td>
<td>in 1 uur</td>
</tr>
</tbody>
</table>

III Supportive care

Voorafgaand aan aanvang therapie sperma en eicellen preservatiemethoden overwegen. Afspraken maken rondom contraceptie.

Ondersteunend ter voorkoming hypokaliëmie en hypomagnesiëmie bij hyperhydratie
Na cisplatin infuus gedurende volgende 16 uur elke 8 uur 20 mmol KCl, 10 mmol MgSO₄ en 0.6 mmol Cagluconaat in 1000 NaCl 0,9%.

Weegprotocol
Ter voorkoming van nefrotoxiciteit bij de cisplatinum wordt hyperhydratie toegepast. Om te voorkomen dat patiënten onder of overvuld raken wordt het weegprotocol gehanteerd. Voor start van de hyperhydratie wordt de patiënt gewogen - dit is het uitgangsgewicht, tijdens de kuur wordt 2xdaags de patiënt gewogen. Indien het gewicht 2 kg boven het uitgangsgewicht is, wordt 20 mg furosemide i.v. gegeven. Bij patiënten met hart- of nieraandoeningen, lymfoedeem of ascites gelden strengere regels.

Anti-emeticasuggestie
Dag 1: aprepitant 120 mg 1xdaags p.o. Dag 2-3: aprepitant 80 mg 1xdaags p.o.
Dag 1-5: ondansetron 8 mg 1xdaags i.v. en zo nodig 1xdaags i.v. extra.

Thuismediate: mee geven
Metoclopramide 10-20 mg 3–4xdaags zo nodig (max 60 mg dd) en ondansetron 8 mg 2xdaags zo nodig.

Bij falen bovenstaande anti-emetica schema:

<table>
<thead>
<tr>
<th>Medicatie</th>
<th>Dosering</th>
<th>Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethason</td>
<td>10 mg i.v.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>dag 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>dag 2–3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>dag 4–5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stop</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 dd 6 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 dd 3 mg</td>
</tr>
</tbody>
</table>

Primary intracranial germ-cell tumours in adults: Treatment Protocol
Revision 1 – version 20220228
Nefrotoxische geneesmiddelen
Zo mogelijk vermijden: diuretica, NSAIDs, calcineurineremmers (tacrolimus, ciclosporine), aminoglycosiden (bijv. gentamycine, tobramycine), amfotericine.

Profy lactische antibiotica
Overwegen: co-trimoxazole 480 mg 1xdaags (PJP profylaxe), ciproxine 500 mg 1xdaags dag 5–15 (atypische verwekkers profylaxe)

IV Dosisaanpassingen en uitstel behandeling

Hematologische toxiciteit
- Bij neutropene koorts: neulasta starten na volgende kuur;
- Bij hematurie (>10 RBC/HPF): ophogen mesna dosis tot 2400 mg/m²/dag en controleren of er een adequate hyperhydratie is gegeven met afdoende urineproductie; blaasspoelingen kunnen worden overwogen. Bij acute ernstige blaasbloedingen onmiddellijk uroloog in consult vragen ter beoordeling van blaasinstillaties aangezien deze bloedingen levensgevaarlijk kunnen worden.

Bij aanvang kuur:
- neutrofiele granulocyten ≥0.5 x 10⁹/l en
- trombocyten ≥100 x 10⁹/l
anders uitstel kuur met 1 week. Als na 1 week het beenmerg hersteld is, wordt de volgende kuur 100% gedoseerd in geval van neutropenie zonder thrombopenie, en wordt granulocyct-Kolonie stimulerende factor (G-CSF, i.e. Neulasta® 6 mg d. 6 SC) toegediend. Als de kuur werd uitgesteld vanwege thrombopenie, of als G-CSF al toegediend was bij de vorige kuur, wordt 25% dosisreductie van etoposide toegepast. Bij >2 weken uitstel ondanks eerder ingestelde dosisreductie etoposide, overleg met medisch oncologen uit team LWNO.

Ototoxiciteit (laagste graad van beste oor)

<table>
<thead>
<tr>
<th>Graad</th>
<th>Subjectief gehoorverlies</th>
<th>Audiometrie</th>
<th>Dosisaanpassing</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>geen verschil</td>
<td>verlies &lt;40 db</td>
<td>Geen</td>
</tr>
<tr>
<td>1</td>
<td>geen verschil</td>
<td>verlies &gt;40 db op 8000 Hz</td>
<td>Geen</td>
</tr>
<tr>
<td>2</td>
<td>tinnitus</td>
<td>verlies &gt;40 db op 4000 Hz</td>
<td>i.p.v.cisplatine carboplatin AUC 4</td>
</tr>
<tr>
<td>3</td>
<td>functie interfererend; nood aan gehoorstoestel</td>
<td>verlies &gt;40 db op 2000 Hz</td>
<td>geen platinum</td>
</tr>
<tr>
<td>4</td>
<td>doofheid niet te corrigeren</td>
<td>verlies &gt;40 db op 1000 Hz</td>
<td>geen platinum</td>
</tr>
</tbody>
</table>

AUC = area under the curve

Nierfunctiestoornissen
- Berekend GFR <60 ml /min/1.73 m²
- Serum creat >1.5 x ULN
Uitstel kuur met 1 week. Vervolgens meten GFR door 24 uurs urine-bepaling. Indien GFR <60 ml /min/1.73 m², vervang cisplatine in carboplatine AUC 6.

Ifosfamide geïnduceerde neurotoxiciteit
Cerebrale bijwerkingen kunnen optreden en karakteriseren zich door verminderd bewustzijn, verwardheid, angst en hallucinaties. Herstel kan dagen tot weken duren. Gunstige effecten zijn waargenomen bij toediening van methyleenblauw 6x50 mg/dag i.v. en van thiamine 6x100 mg in 100 cc NaCl 0.9% in 10 minuten i.v. Na eenmaal opgetreden neurotoxiciteit dient bij vervolgkuren profy lactisch methyleenblauw 6 dd 50 mg IV te worden toegediend.
Endocrinopathie
In geval van diabetes insipidus wordt een consult bij een endocrinoloog aanbevolen om ernstige electrolytstoornissen te voorkomen. Bijzondere aandacht is vereist voor vochtbalans en plasma electrolyten in deze patiënten, met name bij patiënten zonder dorstgevoel.

V Routine bepalingen tijdens behandeling

1) Voor aanvang behandeling (op indicatie): audiometrie, ECG, gemeten GFR (24-uurs urine).
2) Voor iedere kuur: gewicht, tensie, pols, L.O. met neurologische evaluatie, Hb, leuco+diff, thrombo, Na, K, Mg, calcium, fosfaat, albumine, ureum, creatinine, berekende GFR bepaling, bilirubine, ASAT, ALAT, AF, γGT, LDH, AFP, βHCG.
3) Tijdens chemotherapie dagelijks urinesediment ter bepaling van microscopische hematurie en kreatinine in bloed bepalen.
4) Einde behandeling: Hb, leuco+diff, thrombo, Na, K, Mg, calcium, fosfaat, albumine, ureum, creatinine, bilirubine, ASAT, ALAT, AF, γGT, LDH, AFP, βHCG, audiometrie, gemeten GFR bepaling (24-uurs urine).

VI Mogelijke bijwerkingen
Mislukking, braken, moeheid, stomatitis, alopecia, hemorrhagische cystitis, leverfunctiestoornissen, beenmergtoxiciteit, infertiliteit, nefrotoxiciteit, neurotoxiciteit, cardiotoxiciteit, ototoxiciteit, allergische reacties, encephalopathie, secundaire tumoren.

VII Evaluatie tijdens behandeling

1) MRI cerebrum +/- contrast na 4 kuren. Overweeg MRI CWK-LWK.
2) AFP, βHCG en cytologie in CSF (bij afwijkingen voor aanvang therapie) na 4 kuren.
3) Overweeg chirurgie bij resectabel restletsel na 4 kuren.
4) Radiotherapie, eventueel gevolgd door re-operatie.

Literatuur

- Behandelschema gebaseerd op SIOP CNS GCT II protocol.
### Appendix B: ZUBROD-ECOG-WHO Performance Status

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Normal activity</td>
</tr>
<tr>
<td>1</td>
<td>Symptoms, but nearly ambulatory</td>
</tr>
<tr>
<td>2</td>
<td>Some bed time, but to be in bed less than 50% of normal daytime</td>
</tr>
<tr>
<td>3</td>
<td>Needs to be in bed more than 50% of normal daytime</td>
</tr>
<tr>
<td>4</td>
<td>Unable to get out of bed</td>
</tr>
</tbody>
</table>
## Appendix C: RTOG neurologic function status

<table>
<thead>
<tr>
<th>Grade</th>
<th>Neurologic Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No neurologic symptoms; fully active at home/work without assistance</td>
</tr>
<tr>
<td>1</td>
<td>Minor neurologic symptoms; fully active at home/work without assistance</td>
</tr>
<tr>
<td>2</td>
<td>Moderate neurologic symptoms; fully active at home/work but requires assistance</td>
</tr>
<tr>
<td>3</td>
<td>Moderate neurologic symptoms; less than fully active at home/work and requires assistance</td>
</tr>
<tr>
<td>4</td>
<td>Severe neurologic symptoms; totally inactive requiring complete assistance at home or institution - unable to work</td>
</tr>
</tbody>
</table>
Appendix D: MR imaging – minimal requirements

MRI scanner - minimally 1.0T (magnetic field strength)

MRI brain
1) unenhanced T1W; T2W; axial; FLAIR axial or coronal.
   - slice thickness no more than 5 mm
   - DWI (diffusion) – optional
2) after gadolinium: T1 W axial; coronal, sagittal; slice thickness no more than 5 mm

MRI spine
1) unenhanced T1W en T2W sagittal; slice thickness no more than 4 mm
2) after gadolineum: T1W sagittal; slice thickness no more than 4 mm
   transversal slices at the level(s) of abnormalities